Nivolumab + Relatlimab
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Untreated Melanoma
Conditions
Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma
Trial Timeline
Nov 15, 2026 → May 28, 2029
NCT ID
NCT07459543About Nivolumab + Relatlimab
Nivolumab + Relatlimab is a approved stage product being developed by Bristol Myers Squibb for Untreated Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07459543. Target conditions include Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma.
What happened to similar drugs?
0 of 3 similar drugs in Untreated Melanoma were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07459543 | Approved | Recruiting |
| NCT06237920 | Phase 2 | Recruiting |
| NCT04658147 | Phase 1 | Active |
| NCT04567615 | Phase 2 | Completed |
| NCT04552223 | Phase 2 | Completed |
| NCT03623854 | Phase 2 | Completed |
| NCT03610711 | Phase 1/2 | Active |
| NCT03642067 | Phase 2 | Completed |
Competing Products
15 competing products in Untreated Melanoma